Form 4 for EW Edwards Lifesciences
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-07 · accession 0001225208-22-006814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-10 | 2022-05-07+ | EW | Lemercier Jean-Luc M | CVP, EMEA, Canada, Latin Amer | F - Tax | $100.52 | -666 | 155.0K | -0.4% | -$66.9K |
| DM | 2022-05-10 | 2022-05-08+ | EW | Lemercier Jean-Luc M | CVP, EMEA, Canada, Latin Amer | M - OptEx | $12.52 | +20.1K | 163.5K | +14% | +$251.5K |
| D | 2022-05-10 | 2022-05-09 | EW | Lemercier Jean-Luc M | CVP, EMEA, Canada, Latin Amer | S - Sale+OE | $98.24 | -11.6K | 162.9K | -7% | -$1.14M |
| DM | 2022-05-10 | 2022-05-08+ | EW | Lemercier Jean-Luc M | CVP, EMEA, Canada, Latin Amer | M - OptEx | $0.00 | -20.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-08 | F | D | 615 | $100.52 | 162,899.34 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-09 | M | A | 11,560 | $21.76 | 174,459.34 | D | — | — | |
| 3 | Common | Common Stock | 2022-05-09 | S | D | 11,560 | $98.24 | 162,899.34 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $97.95 to $98.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2022-05-08 | M | A | 8,531 | $0.00 | 163,514.34 | D | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 5 | Common | Common Stock | 2022-05-07 | F | D | 51 | $100.52 | 154,983.34 | D | — | — | |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-09 | M | D | 11,560 | $0.00 | 0 | D | $21.76 · 2016-05-14 to 2022-05-13 | 11,560 Common Stock | |
| 7 | Derivative | Performance Rights | 2022-05-08 | M | D | 8,531 | $0.00 | 0 | D | — · 2022-05-08 to 2026-05-07 | 8,531 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |